This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (113)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of a Matched Case-Control Study

Barry M. Farr, MD, MSc; B. Lynn Johnston, MD; David K. Cobb, MD; Michael J. Fisch, MD; Teresa P. Germanson, MPH, PhD; Karim A. Adal, MD, MS; Anne M. Anglim, MD, MS

Arch Intern Med. 1995;155(21):2336-2340.

Abstract
Background
Three randomized controlled trials of the effectiveness of pneumococcal vaccine in elderly and chronically ill adults in the United States have failed to show significant protective efficacy during 44 213 person-years of follow-up. Case-control studies have greater statistical power to detect significant prevention of rare diseases such as pneumococcal bacteremia, but they also have a greater susceptibility to bias, necessitating consistent results from multiple studies. Three case-control studies at two different universities have shown prevention of systemic infection, but another study found no benefit.

Methods
Patients with pneumococcal bacteremia who were at least 2 years old and had chronic illness indicating the need for pneumococcal vaccine, or who were at least 65 years old were compared with matched control subjects for frequency of prior vaccination. Matching variables included date of admission, age, sex, race, type and duration of chronic illness serving as the major vaccine indication, number of vaccine indications and number of medical hospitalizations since licensure of the pneumococcal vaccine in 1978, and type of primary medical care.

Results
Pneumococcal vaccination was documented in the records of six (7%) of 85 cases and 26 (17%) of 152 control subjects, suggesting 81% efficacy in conditional logistical regression analysis (95% confidence interval, 34% to 94%, P=008).

Conclusions
Four case-control studies at three universities have now demonstrated significant protective efficacy of pneumococcal vaccine for preventing pneumococcal bacteremia. The development of antibiotic-resistant Streptococcus pneumoniae indicates an urgent need for an increased rate of vaccination among high-risk patients and for the development of more immunogenic conjugate vaccines that may enhance efficacy among elderly and immunocompromised patients as well as infants.

(Arch Intern Med. 1995;155:2336-2340)

Author Affiliations
From the University of Virginia Health Sciences Center, Charlottesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Invasive Pneumococcal Disease Among White Mountain Apache Adults, 1991-2005
Bliss et al.
Arch Intern Med 2008;168:749-755.
ABSTRACT | FULL TEXT  

Guidelines for the management of adult lower respiratory tract infections
Woodhead et al.
Eur Respir J 2005;26:1138-1180.
ABSTRACT | FULL TEXT  

An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting
Mangtani et al.
Int J Epidemiol 2005;34:565-574.
ABSTRACT | FULL TEXT  

Additive preventive effect of influenza and pneumococcal vaccines in elderly persons
Christenson et al.
Eur Respir J 2004;23:363-368.
ABSTRACT | FULL TEXT  

Preventive Health Care in the Elderly Population: A Guide for Practicing Physicians
Takahashi et al.
Mayo Clin Proc. 2004;79:416-427.
ABSTRACT  

Pneumococcal Vaccination and Revaccination of Older Adults
Artz et al.
Clin. Microbiol. Rev. 2003;16:308-318.
ABSTRACT | FULL TEXT  

Failure to Vaccinate Medicare Inpatients: A Missed Opportunity
Bratzler et al.
Arch Intern Med 2002;162:2349-2356.
ABSTRACT | FULL TEXT  

Quality Indicators for the Management of Pneumonia in Vulnerable Elders
Rhew
ANN INTERN MED 2001;135:736-743.
FULL TEXT  

Pneumococcal vaccination: current and future issues
Ortqvist
Eur Respir J 2001;18:184-195.
ABSTRACT | FULL TEXT  

Evaluation of Effectiveness of the 23-Valent Pneumococcal Capsular Polysaccharide Vaccine for HIV-Infected Patients
Breiman et al.
Arch Intern Med 2000;160:2633-2638.
ABSTRACT | FULL TEXT  

The Health and Economic Benefits Associated With Pneumococcal Vaccination of Elderly Persons With Chronic Lung Disease
Nichol et al.
Arch Intern Med 1999;159:2437-2442.
ABSTRACT | FULL TEXT  

Prognosis After Community-Acquired Pneumonia in the Elderly: A Population-Based 12-Year Follow-up Study
Koivula et al.
Arch Intern Med 1999;159:1550-1555.
ABSTRACT | FULL TEXT  

The place of pneumococcal vaccination
DTB 1998;36:73-76.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Vaccination Against Pneumococcal Bacteremia Among Elderly People
Sisk et al.
JAMA 1997;278:1333-1339.
ABSTRACT  

Adult Bacteremic Pneumococcal Pneumonia in a Community Teaching Hospital, 1992-1996n: A Detailed Analysis of 108 Cases
Watanakunakorn and Bailey
Arch Intern Med 1997;157:1965-1971.
ABSTRACT